by The global Escherichia Coli Strain Market is estimated to be valued at US$ 1.97 Bn in 2023 and is expected to exhibit a CAGR of 6.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Escherichia Coli (E.Coli) strains have wide applications in research and biotechnology industries. Commonly used E.Coli K-12strain is very helpful for DNA cloning and protein expression. While probiotic E.Coli strains are gaining importance for developing digestive health supplements.
Market key trends:
One of the key trends in the market is growing adoption of genetically modified E.Coli strains for specialized applications. Genetic engineering is allowing development of E.Coli strains for producing biofuels, developing vaccines, and bioremediation. Researchers are modifying genes of standard E.Coli strains like K-12 to endow them with abilities to degrade toxic pollutants, produce hydrogen as biofuel, or express antigens for vaccine development. These engineered strains have potential to contribute significantly in respective application areas in coming years.
Segment Analysis
The global Escherichia coli strain market is segmented by strain type into K-12 strains, non-K12 strains and others. Among these, the K-12 strains segment dominates the market and accounts for the largest market share. K-12 strains are the most commonly used E. coli strains in research and molecular cloning experiments as they are considered as safe laboratory strains with low endotoxin levels and well-characterized genotype. These factors have resulted in the wide use of K-12 strains for various purposes like genetic engineering, protein expression and diagnostics etc.
Key Takeaways
Global Escherichia Coli Strain Market Demand is expected to witness high growth, exhibiting CAGR of 6.9% over the forecast period, due to increasing research activities in fields of genomics and synthetic biology.
The North America region is expected to dominate the E. coli strain market during the forecast period. This is attributed to rising R&D funding for genomics and synthetic biology research from both public and private sectors in countries like US and Canada.
Key players operating in the Escherichia coli strain market are Thermo Fisher Scientific Inc., Merck KGaA, Novozymes A/S, QIAGEN N.V., Promega Corporation, Agilent Technologies, Inc., New England Biolabs, Inc., Takara Bio Inc., Bio-Rad Laboratories, Inc., GenScript Biotech Corporation. Thermo Fisher Scientific Inc. is currently the market leader in E. coli strain space owing to its wide product portfolio and global brand recognition.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
